NCT02264210View on ClinicalTrials.gov

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

PHASE2CompletedINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

July 31, 2022

Conditions

Lung NeoplasmsSquamous Cell Lung CancerAdenocarcinoma of the LungAdenosquamous Cell Lung CancerLarge Cell Lung CancerBronchial NeoplasmsStage IB Non-small Cell Lung Cancer

Interventions

DRUG

Icotinib

Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT02264210 - Icotinib for Completed Resected IB NSCLC With EGFR Mutation | Biotech Hunter | Biotech Hunter